Explanation of Procedure

Intralesional chemotherapy is a clinical trial abdresults are yet

to be published. The tumors most commonly treated are: osteosarcoma, oral melanoma and other oral tumors, soft tissue sarcomas, vaccine sarcomas, mast cell tumors, and squamous cell tumors. This procedure is used to control pain, to prevent or delay recurrence of a tumor after surgical removal, or to decrease the size of a tumor that has not been surgically removed.
Treatment Protocol

Intralesional chemotherapy treatment protocols are subject to change based on the patient’s response to treatment. Intralesional chemotherapy may be used as a sole agent or in combination with systemic chemotherapy (oral or injectable) for all or part of the therapy.

Benefits

Intralesional treatment can be used to keep a patient more comfortable. By administering chemotherapy directly into a tumor or the area around a tumor rather than systemically, patients experience fewer side effects. 

Risks and Discomforts

Minimal local toxicity has been reported and this treatment is generally well tolerated. There have been reports of tissue reactions, infections, abscesses, and granuloma formation. There are also reports of swelling, tissue death, ulceration, dehiscence and wound formation; all of which have resolved with treatment. Side effects can occur immediately or days after treatment. With supportive care, side effects should resolve within a few days.

Intralesional chemotherapy is considered experimental. Some of the drugs used in this clinical trial may not be used in accordance with the approved labeling. This extra-label drug use is in accordance with the Animal Medicinal Drug Use Clarification Act (AMDUCA)